ARMP Armata Pharmaceuticals, Inc.

27

Healthcare [ 5/11 ] | Biotechnology [ 53/112 ]

US | AMEX | Stock

Price
$1.34
Decreased by -0.04%
Dollar Volume (20D)
10.37 K
ADR%
9.33
Earnings Report Date (estimate)
Aug 9, 23 (-0.37)
Market Cap.
48.43 M
Shares Float
10.99 M
Shares Outstanding
36.14 M
Beta
0.54
Price / Earnings
-1.11
BPR
30.97
20D Range
1.21 1.68
50D Range
1.21 1.93
200D Range
0.83 4.92
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 11, 23 -0.40
Decreased by -33.33%
 -0.32
Decreased by -78.13%
Mar 16, 23 -0.29
Decreased by -26.09%
 -0.28
Decreased by -12.76%
Nov 9, 22 -0.24
Decreased by -9.09%
 -0.28
Increased by +51.02%
Aug 11, 22 -0.26
Decreased by -4.00%
 -0.23
Decreased by -56.71%
May 12, 22 -0.30
Decreased by -11.11%
 -0.21
Decreased by -204.08%
Mar 17, 22 -0.23
Increased by +36.11%
 -0.28
Increased by +63.78%
Nov 10, 21 -0.22
Increased by +29.03%
 -0.26
Increased by +59.17%
Aug 12, 21 -0.25
Increased by +3.85%
 -0.26
Increased by +14.79%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 0.00
Decreased by N/A%
 -17.63 M
Decreased by -101.00%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0.00
Decreased by N/A%
 -10.30 M
Decreased by -70.35%
Decreased by N/A%
Decreased by N/A%
Sep 30, 22 0.00
Decreased by N/A%
 -8.61 M
Decreased by -58.79%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by N/A%
 -9.21 M
Decreased by -48.69%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by N/A%
 -8.77 M
Decreased by -59.65%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
 -6.05 M
Increased by +8.71%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
 -5.42 M
Increased by +6.07%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 0.00
Decreased by -100.00%
 -6.19 M
Decreased by -31.51%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.